Andrew Cooper
Stock Analyst at Raymond James
(2.40)
# 2,468
Out of 4,944 analysts
147
Total ratings
44.27%
Success rate
-1.45%
Average return
Main Sectors:
Stocks Rated by Andrew Cooper
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HAE Haemonetics | Downgrades: Outperform | $105 → $78 | $52.23 | +49.34% | 10 | Aug 11, 2025 | |
| AZTA Azenta | Upgrades: Outperform | $35 | $30.79 | +13.67% | 2 | Aug 6, 2025 | |
| AVTR Avantor | Reiterates: Outperform | $16 → $14 | $12.73 | +9.98% | 15 | Aug 4, 2025 | |
| GH Guardant Health | Maintains: Outperform | $59 → $61 | $56.51 | +7.95% | 4 | Jul 31, 2025 | |
| RVTY Revvity | Reiterates: Outperform | $120 → $115 | $88.55 | +29.87% | 9 | Jul 29, 2025 | |
| ITGR Integer Holdings | Maintains: Outperform | $150 → $143 | $108.42 | +31.89% | 3 | Jul 25, 2025 | |
| TMO Thermo Fisher Scientific | Reiterates: Outperform | $525 → $535 | $482.74 | +10.83% | 7 | Jul 24, 2025 | |
| MYGN Myriad Genetics | Reiterates: Outperform | $19 → $10 | $6.06 | +65.02% | 5 | May 7, 2025 | |
| FLGT Fulgent Genetics | Reiterates: Outperform | $24 → $25 | $21.24 | +17.70% | 2 | May 5, 2025 | |
| HOLX Hologic | Reiterates: Outperform | $90 → $71 | $68.18 | +4.14% | 12 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $222.06 | - | 1 | Mar 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $206.94 | - | 8 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Perform | n/a | $42.58 | - | 8 | Sep 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $12.51 | - | 16 | May 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $68 → $85 | $157.44 | -46.01% | 5 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Outperform | $100 → $76 | $25.85 | +194.00% | 12 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | n/a | $4.10 | - | 1 | Jul 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $6.21 | - | 14 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $29.19 | - | 8 | Jan 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.85 | - | 5 | Sep 22, 2021 |
Haemonetics
Aug 11, 2025
Downgrades: Outperform
Price Target: $105 → $78
Current: $52.23
Upside: +49.34%
Azenta
Aug 6, 2025
Upgrades: Outperform
Price Target: $35
Current: $30.79
Upside: +13.67%
Avantor
Aug 4, 2025
Reiterates: Outperform
Price Target: $16 → $14
Current: $12.73
Upside: +9.98%
Guardant Health
Jul 31, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $56.51
Upside: +7.95%
Revvity
Jul 29, 2025
Reiterates: Outperform
Price Target: $120 → $115
Current: $88.55
Upside: +29.87%
Integer Holdings
Jul 25, 2025
Maintains: Outperform
Price Target: $150 → $143
Current: $108.42
Upside: +31.89%
Thermo Fisher Scientific
Jul 24, 2025
Reiterates: Outperform
Price Target: $525 → $535
Current: $482.74
Upside: +10.83%
Myriad Genetics
May 7, 2025
Reiterates: Outperform
Price Target: $19 → $10
Current: $6.06
Upside: +65.02%
Fulgent Genetics
May 5, 2025
Reiterates: Outperform
Price Target: $24 → $25
Current: $21.24
Upside: +17.70%
Hologic
May 2, 2025
Reiterates: Outperform
Price Target: $90 → $71
Current: $68.18
Upside: +4.14%
Mar 28, 2025
Initiates: Market Perform
Price Target: n/a
Current: $222.06
Upside: -
Feb 3, 2025
Downgrades: Market Perform
Price Target: n/a
Current: $206.94
Upside: -
Sep 26, 2024
Reiterates: Market Perform
Price Target: n/a
Current: $42.58
Upside: -
May 13, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $12.51
Upside: -
Feb 20, 2024
Downgrades: Outperform
Price Target: $68 → $85
Current: $157.44
Upside: -46.01%
Feb 14, 2024
Downgrades: Outperform
Price Target: $100 → $76
Current: $25.85
Upside: +194.00%
Jul 19, 2023
Initiates: Market Perform
Price Target: n/a
Current: $4.10
Upside: -
May 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.21
Upside: -
Jan 18, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $29.19
Upside: -
Sep 22, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $2.85
Upside: -